Earnings call transcript: Phreesia surpasses Q1 2025 earnings forecasts, stock climbs

Phreesia Inc. reported a strong Q1 2025, exceeding EPS expectations at -$0.07 versus the forecasted -$0.12, and revenue slightly above estimates at $115.9 million, a 15% year-over-year increase. The company's stock saw a 3.33% rise in premarket trading following the announcement, reflecting investor confidence. Phreesia also raised its adjusted EBITDA outlook for the full year to $85-$90 million, driven by product expansion and network growth, while maintaining a focus on AI and product innovation.

Analysis

Phreesia Inc. (PHR) reported a robust first quarter for fiscal year 2026, exceeding analyst expectations with an earnings per share (EPS) of -$0.07 against a forecast of -$0.12, and revenue of $115.9 million, up 15% year-over-year and slightly above the anticipated $114.92 million. This performance, driven by strong product adoption and client growth (70 new healthcare services clients added), contributed to a 3.33% premarket stock increase. The company demonstrated notable financial health improvements, including a gross margin of 67.86%, adjusted EBITDA growth of 16.7% year-over-year to $20.8 million (an 18% margin), and its fourth consecutive quarter of positive operating cash flow ($14.9 million) and free cash flow ($7.5 million). Reflecting this strength, Phreesia raised its full-year adjusted EBITDA outlook to $85-$90 million, while maintaining its revenue forecast of $472-$482 million and its target of approximately 4,500 average healthcare services clients. Management emphasized continued investment in AI and product innovation as key growth drivers, aiming to provide solutions to complex client problems rather than just selling technology. InvestingPro analysis suggests the stock trades below fair value with expectations of net income growth and future profitability, further supported by a recently authorized share repurchase program. Despite these positive indicators, the company operates in a competitive healthcare services market and acknowledges risks associated with macroeconomic volatility and AI integration.

Key Decisions for Investors

• Given Phreesia's strong Q1 FY26 earnings beat, upward revision of its adjusted EBITDA guidance, and consistent free cash flow generation, investors may consider the current valuation, noted by InvestingPro as below Fair Value, for potential accumulation.
• Investors should closely monitor the company's progress in adding new healthcare services clients towards its fiscal 2026 target of approximately 4,500, and the growth in total revenue per average healthcare services client, as these are critical to achieving its revenue objectives.
• The successful execution of Phreesia's AI integration and product innovation strategy warrants careful observation, as these are pivotal for sustained competitive advantage and long-term value creation in the evolving healthcare technology landscape.
• While the financial outlook is positive, including the flexibility offered by the new share repurchase program, it is prudent to weigh the acknowledged risks, such as market competition and macroeconomic factors, which could influence future performance.